New Hope: Tech Boosts Survival in Pediatric Liver Transplants

DULUTH, Ga. – April 24, 2026 – By Charles Rivera

A groundbreaking organ preservation technology is showing unprecedented success in pediatric liver transplantation, offering new hope to the most vulnerable patients and promising to redefine the standard of care. New clinical data presented today demonstrates that Bridge to Life's VitaSmart Hypothermic Oxygenated Machine Perfusion (HOPE) System not only makes pediatric liver transplants safer but also has the potential to expand the critically scarce pool of available donor organs for children.

The findings, unveiled at the 30th annual meeting of the Society of Pediatric Liver Transplantation (SPLIT) in San Francisco, highlight a significant leap forward from the traditional method of storing organs on ice. For decades, the success of a transplant has been a race against time. The new data suggests that this technology can turn back the clock on organ damage, improving outcomes for children who desperately need a second chance at life.

A New Standard of Care on the Horizon

The most compelling evidence came from a study presented by Dr. Karla Estefanía of Birmingham Children's Hospital in the UK. Her team's research focused on the use of partial liver grafts—either split or reduced-size livers—which are essential for matching adult donor organs to small children. These delicate procedures make the grafts particularly susceptible to injury.

In a study involving 17 pediatric recipients, the use of the VitaSmart HOPE system yielded remarkable results: 100% death-censored graft survival. Furthermore, there were no observed cases of primary non-function, a catastrophic event where the transplanted organ fails to work, or early ischemic-type biliary lesions, a severe complication that can lead to graft loss. Critically, the system achieved an estimated 27 percent reduction in cold ischemic time—the period the organ is without blood supply—which is vital for ensuring the organ's long-term viability.

"Our study with 17 pediatric liver recipients adds to the growing evidence supporting the ability of HOPE to improve donor liver quality in pediatric liver transplantation," commented Dr. Estefanía during her presentation. Based on the exceptional outcomes, she concluded that HOPE "can become a standard of care for partial graft utilization in pediatric liver transplantation."

This sentiment was echoed by additional research presented at the conference. Two abstracts from La Paz University Hospital in Madrid, Spain, detailed their own positive experiences. One study, covering 35 diverse and complex pediatric cases, concluded that HOPE is a safe and effective strategy that has already become the standard of care within their program for suboptimal and reduced-size grafts. Another case report highlighted its successful use in a critically ill child with acute liver failure, demonstrating its potential in emergency situations.

Beyond the Icebox: The Science of Organ Rejuvenation

For decades, the standard procedure for organ preservation has been static cold storage (SCS)—essentially placing the organ in a sterile bag with a preservation solution and putting it on ice. While this slows down metabolic processes, it does not stop cellular degradation and can lead to significant ischemia-reperfusion injury, an inflammatory cascade that occurs when blood flow is restored to the organ.

Machine perfusion technologies represent a paradigm shift. Bridge to Life’s VitaSmart system utilizes Hypothermic Oxygenated Machine Perfusion (HOPE). Instead of just sitting dormant, the donor liver is connected to a device that gently pumps a cold, oxygen-rich preservation fluid through its vascular system. This process actively re-energizes the organ's cells, flushes out toxins, and repairs some of the cellular damage incurred during donation. By the time the organ reaches the recipient, it is in a healthier, more robust state.

This active preservation is particularly crucial for what are known as extended criteria donor (ECD) organs, including those from donation after circulatory death (DCD). These organs are more common but are also more prone to injury, making them a higher risk for transplantation, especially in children. By rehabilitating these grafts, the VitaSmart HOPE system can potentially make thousands of previously unusable organs viable for transplant, directly addressing the organ shortage.

"This is a game-changer for us," noted a leading pediatric transplant surgeon unaffiliated with the studies. "We are often dealing with less-than-perfect organs out of necessity. Technology that can repair and optimize these grafts before they even go into the child is exactly what we've been waiting for."

From Lab to Bedside: A Path Paved with Innovation

The technology's arrival in operating rooms is the culmination of years of research and a strategic regulatory pathway. While the VitaSmart system has carried a CE Mark and been used in over 5,000 liver perfusions across Europe and other global markets, its entry into the United States is recent and significant. In January 2026, the U.S. Food and Drug Administration (FDA) granted the system a De Novo approval, establishing a new regulatory classification and making it the first and only FDA-approved hypothermic oxygen perfusion system for liver transplantation in the country.

The commercial rollout in the U.S. began swiftly. In March 2026, Duke University Hospital became the first American transplant center to successfully implement the VitaSmart HOPE System for a commercial case, signaling strong physician confidence in the technology's potential.

"This study out of Birmingham Children's Hospital confirms previous studies in pediatric liver transplantation, even in partial liver grafts, and further demonstrates that HOPE with VitaSmart™ offers an important new tool for the transplantation community," commented Don Webber, CEO and President of Bridge to Life Ltd., in a statement. He emphasized the company's commitment to "increasing the supply of available livers for transplantation, potentially improving access for those in need."

By making more organs viable and improving the quality of all grafts, the technology not only promises better outcomes for individual patients but also has the potential to shorten waitlists, reduce waitlist mortality, and make the entire transplant system more efficient and equitable. For the hundreds of children waiting for a life-saving liver, this innovation represents more than just a medical advancement—it represents a tangible bridge to a healthier future.